Cardiff Oncology Inc. (NASDAQ: CRDF) is 291.94% higher on its value in year-to-date trading and has touched a low of $0.70 and a high of $5.75 in the current 52-week trading range. The CRDF stock was last observed hovering at around $4.86 in the recent trading session, with the current gains setting it 0.04% off its average median price target of $14.50 for the next 12 months. It is also 78.7% off the consensus price target high of $23.00 offered by 2 analysts, but current levels are 18.33% higher than the price target low of $6.00 for the same period.
Even if you’re not actively in crypto, you deserve to know what’s actually going on...
Because while leading assets such as Bitcoin (BTC) and Ethereum (ETH) are climbing in value, a select group of public “crypto stocks” are surging right along with them. More importantly, these stocks are outpacing the returns these leading crypto assets aren already producing.
Click here to get the full story… along with our long list of backdoor Bitcoin strategies. It’s free.
At last check, trading at $4.90, the stock is 32.52% and 85.90% above its SMA20 and SMA50 respectively. However, with a current trading volume of 0.61 million and changing 0.82% at the moment leaves the stock 191.04% off its SMA200. CRDF registered 108.58% gain for a year compared to 6-month gain of 301.65%. The firm has a 50-day simple moving average (SMA 50) of $3.2588 and a 200-day simple moving average (SMA200) of $2.5446.
The stock witnessed a 51.40% loss in the last 1 month and extending the period to 3 months gives it a 521.01%, and is -4.33% down over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 13.09% over the week and 14.77% over the month.
Cardiff Oncology Inc. (CRDF) has around 14 employees, a market worth around $103.28M and $0.30M in sales. Distance from 52-week low is 599.00% and -14.78% from its 52-week high. The company has generated returns on investments over the last 12 months (-228.50%).
Cardiff Oncology Inc. (CRDF) Analyst Forecasts
Analyst recommendations provided by FactSet shows that the consensus forecast for Cardiff Oncology Inc. (CRDF) is a “Buy”. 2 analysts offering their recommendations for the stock have an average rating of 2.00, where 0 rate it as a Hold and 0 think it is a “Overweight”. 2 of the analysts rate the stock as a “Buy”. 0 analysts have rated the stock as a Sell or Underperform.
Cardiff Oncology Inc. is expected to release its quarterly report on 07/31/2020 and quarterly earnings per share for the current quarter are estimated at $0.The EPS is expected to grow by 66.20% this year, but quarterly earnings will post -71.40% year-over-year.
Cardiff Oncology Inc. (CRDF) Top Institutional Holders
26 institutions hold shares in Cardiff Oncology Inc. (CRDF), with 23.5k shares held by insiders accounting for 0.19% while institutional investors hold 11.42% of the company’s shares. The shares outstanding are 9.91M, and float is at 8.56M with Short Float at 3.66%. Institutions hold 11.40% of the Float.
The top institutional shareholder in the company is Vanguard Group, Inc. (The) with over 0.27 million shares valued at $0.27 million. The investor’s holdings represent 1.57% of the CRDF Shares outstanding. As of Mar 30, 2020, the second largest holder is Renaissance Technologies, LLC with 0.14 million shares valued at $0.14 million to account for 0.81% of the shares outstanding. The other top investors are Elkhorn Partners Limited Partnership which holds 33700.0 shares representing 0.20% and valued at over $34037.0, while Prospera Financial Services holds 0.13% of the shares totaling 23270.0 with a market value of $23502.0.
Cardiff Oncology Inc. (CRDF) Insider Activity
A total of 8 insider transactions have happened at Cardiff Oncology Inc. (CRDF) in the last six months, with sales accounting for 0 and purchases happening 8 times.